Connect Biopharma Holdings Net Change in Intangible Assets 2021-2025 | CNTB

Connect Biopharma Holdings net change in intangible assets from 2021 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.

Connect Biopharma Holdings Net Change in Intangible Assets 2021-2025 | CNTB

Connect Biopharma Holdings net change in intangible assets from 2021 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.9B
Amgen (AMGN)$155B
Gilead Sciences (GILD)$141.4B
Vertex Pharmaceuticals (VRTX)$99.8B
Bristol Myers Squibb (BMY)$96.9B
GSK (GSK)$81.3B
CSL (CSLLY)$67.8B
Regeneron Pharmaceuticals (REGN)$62.2B
Alnylam Pharmaceuticals (ALNY)$59.5B
Argenex SE (ARGX)$43.3B
Insmed (INSM)$28.4B
BioNTech SE (BNTX)$24.8B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16B
Genmab (GMAB)$15.9B
Illumina (ILMN)$15.3B
Ascendis Pharma (ASND)$11.8B
BioMarin Pharmaceutical (BMRN)$11.3B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.7B
Exelixis (EXEL)$10.4B
Moderna (MRNA)$9.8B
Verona Pharma American Depositary Share (VRNA)$9.1B
Exact Sciences (EXAS)$8.8B
Bio-Techne Corp (TECH)$8.8B
Halozyme Therapeutics (HALO)$8.6B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.2B